桑托西醇胺改善肝脏葡萄糖代谢,通过调节STZ诱导的T2DM大鼠的肠道微生物群
Xiaowei Peng1, Bing Yang2, Xunyu Wei1
1College of Food Science, Southwest University, 2 Tiansheng Road, Beibei, Chongqing 400715, PR China.
Fitoterapia
|May 17, 2025
概括
尚基胺 (ZA) 通过恢复短链脂肪酸 (SCFA) 生产和改善肠道微生物群,有效地治疗大鼠的2型糖尿病 (T2DM). ZA还激活肝脏的关键通路,提供新的治疗策略.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 是一种复杂的代谢障碍.
- 尚基胺 (ZA) 显示出对T2DM管理的潜力.
- 肠道微生物群和短链脂肪酸 (SCFA) 参与T2DM病变的发生.
研究的目的:
- 在大鼠模型中研究ZA对T2DM的影响.
- 分析器官指数,c-,脂质水平,肠道微生物群和SCFA生产的变化.
- 阐明ZA治疗作用背后的分子机制.
主要方法:
- 在老鼠中诱导T2DM.
- ZA. 的管理.
- 评估器官指数,血液参数和c-水平.
- 用于肠道微生物群分析的16S rRNA测序.
- 对SCFA水平的测量.
- 肝脏PI3K/Akt/mTOR通路的西部斑分析.
主要成果:
- ZA治疗改善了T2DM症状,包括有机巨和脂质失调症.
- 在T2DM大鼠中,ZA恢复并增强了SCFA的产生.
- 肠道微生物群的多样性增加,主要族群的比例发生了变化 (蛋白质细菌,动态细菌,细菌菌/细菌菌).
- ZA激活了肝脏中的PI3K/Akt/mTOR通路,改善了胰岛素的信号传递.
结论:
- 桑托西醇胺显示出对2型糖尿病有显著的治疗潜力.
- ZA调节肠道微生物群和SCFA的产生,有助于其疗效.
- 激活PI3K/Akt/mTOR通路是ZA抗糖尿病作用的关键机制.
- ZA为T2DM诊断,治疗和药物发现提供了有前途的途径.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
01:24Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
01:23Dipeptidyl Peptidase 4 Inhibitors
146
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
146
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
134
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
134